NeuroPace (NPCE) News Today

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of NeuroPace in a research report issued on Wednesday, August 14th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of (

Vanguard Group Inc. boosted its position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 18.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 488,618 shares of the company's stock after purchasing an additional 75,51

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for NeuroPace in a research report issued on Tuesday, August 13th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per sha

NeuroPace (NASDAQ:NPCE - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 173.62% and a negative net margin of 45.61%. The business's revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.36) EPS.

Cantor Fitzgerald reissued an "overweight" rating and issued a $18.00 target price on shares of NeuroPace in a research report on Wednesday.

Wells Fargo & Company reduced their price target on NeuroPace from $20.00 to $15.00 and set an "overweight" rating on the stock in a research report on Wednesday.

NeuroPace (NASDAQ:NPCE) will be releasing earnings after the market closes on Tuesday, August 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=611719)

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the compan

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 74,200 shares, a decline of 40.9% from the May 15th total of 125,500 shares. Based on an average daily volume of 114,000 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's shares are short sold.

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for shares of NeuroPace in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $0.27 f

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 24,609 shares of the stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $14.05, for a total value of $345,756.45. Following the sale, the insider now owns 3,459,113 shares in the company, valued at approximately $48,600,537.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 2,623 shares of the company's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $14.06, for a total transaction of $36,879.38. Following the sale, the insider now directly owns 3,501,975 shares in the company, valued at $49,237,768.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 461,899 shares of the firm's stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $14.49, for a total value of $6,692,916.51. Following the completion of the sale, the insider now owns 3,542,068 shares in the company, valued at $51,324,565.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rat

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 85,900 shares, a growth of 178.0% from the March 15th total of 30,900 shares. Currently, 0.7% of the company's shares are short sold. Based on an average trading volume of 98,900 shares, the short-interest ratio is currently 0.9 days.

Kent Lake Capital LLC grew its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 670,946 shares of the company's stock after acquiring an additional 96,529 shares during the